Galderma Announced The Phase Iii Olympia 2 Trial Met All Primary And Key Secondary Endpoints, Showing Nemolizumab As Monotherapy Significantly Improved Skin Lesions And Pruritus (Itch) Compared With Placebo In Adult Patients With Moderate To Severe Prurigo Nodularis. The Safety Profile Was Consistent With The Phase Ii Trial Results.
